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CObjective: The prevalence of type 2 diabetes has shown a significant in-
crease in parallel with health care costs. The objective of the Brazilian
Study on Diabetes Costs (ESCUDI study) was to estimate direct and indi-
rect costs of type 2 diabetes outpatient care in the Brazilian Public Health
Care System. Methods: Data were collected from different levels of
health care in eight Brazilian cities in 2007. A total of 1000 outpatients
were interviewed and had their medical records data analyzed. Direct
medical costs included expenses withmedications, diagnostic tests, pro-
cedures, blood glucose test strips, and office visits. Nonmedical direct
costs included expenses with diet products, transportation, and caregiv-
ers. Absenteeism, sick leave, and early retirement were classified as indi-
rect costs.Results: Total annual cost for outpatient carewasUS$2108 per
atient, out of which US$1335 per patient of direct costs (63.3%) and




oi:10.1016/j.jval.2011.05.009iabetes and level of health care increased. Patients with both microvas-
ular and macrovascular complications had higher costs (US$3199 per
atient) compared to those with either microvascular (US$2062 per pa-
ient) or macrovascular (US$2517 per patient) complications only. The
reatest portion of direct costs was attributed to medication (48.2%).
onclusions: Diabetes treatment leads to elevated costs both to Brazilian
ublic Health Care System and society. Costs increased along with dura-
ionof disease, level of care andpresence of chronic complications,which
uggested a need to reallocate health resources focusing on primary pre-
ention of diabetes and its complications.
eywords: Brazil, costs, outpatient care, type 2 diabetes.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The prevalence of diabetes in all age groups worldwide had been
estimated to reach 2.8% in 2000 and 4.4% by 2030. By then, the total
number of people with diabetes is projected to rise from 171 mil-
lion to 366million [1]. Nearly two-thirds of individuals with diabe-
tes live in developing countries such as Brazil, India, and China,
where this number is expected to increase during the next two
decades [2]. A single nationwide study was carried out in Brazil in
the late 1980s and results showed 7.6% prevalence of diabetes in
people aged 30 to 69 years [3]. It is remarkable that nearly 50% of
those diagnosedwith diabeteswere not aware of their disease and
only 25% reported receiving care. More recent regional studies
showed an increase in prevalence rates: 12.1% in the city of Ri-
beirão Preto [4], 12.4% in Porto Alegre [5], and 13.5% in São Carlos
[6].
The Brazilian Public Health System (SUS) consists of a network
of district or basic health care units, hospitals, laboratories, and
blood banks essentially institutionalized to provide all Brazilian
citizens with comprehensive care.
Conflicts of interest: The authors have indicated that they hav
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ublished by Elsevier Inc.Because direct and indirect costs of diabetes in Brazil are
unknown, public health policymakers and managers cannot
properly assess the real needs of patients with diabetes. There-
fore, different management approaches are inadequately eval-
uated and resources are not correctly and sufficiently allocated.
Moreover, the difficulty in accessing health services makes it
even harder to measure the actual burden of diabetes in Brazil.
In 2007, the Brazilian Society of Diabetes created aworking group
with the purpose of estimating diabetes care costs in Brazil. Initially,
the group conducted the Brazilian Study on Diabetes Costs (ESCUDI
study) to estimate direct and indirect costs of outpatient care of a
selected sample of type 2 diabetes patients in the SUS.
Subjects and methods
A retrospective study based on data collected from different levels
of care (primary, secondary, and tertiary care units) in eight Bra-
zilian citieswas carried out during the year 2007. Those citieswere
selected based on geographical criteria (northwest, south, and
southeast), where health services were fairly organized, medical
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diabetes was being conducted by local experienced investigators.
The study design included 50 patients per level of care, a total of
100patients frommedium-sized cities (Bauru, Itabuna, andCampina
Grande) and 150 patients from large cities (Fortaleza, Rio de Janeiro,
Porto Alegre, Ribeirão Preto, and São Paulo). In the city of São Paulo,
the only patients included were the ones from the secondary and
tertiary levels; altogether the final sample comprised 1000 patients.
The inclusion criteria were being older than age 30 years and
having been followed-up at the health center for at least 1 year.
Exclusion criteria were being pregnant, older than age 75 years,
or having other diseases (human immunodeficiency virus, cancer,
or hepatic failure) that could significantly affect the analy-
sis of resource use. Patients scheduled to attend the centers were
randomly selected for a face-to-face interview, which consisted of
a questionnaire developed by the main research group. The basis
of such research instrument came from a Pan American Health
Organization questionnaire, which had been previously used in
the Caribbean. The questionnaire was tested with 15 individuals
and amendments were made. It was administered in two phases:
patient data were collected through personal interviews, and then
data were collected by systematically reviewing medical records.
The subjects were classified into groups: those who hadmicro-
vascular (retinopathy, neuropathy, or nephropathy) and/or mac-
rovascular (cerebrovascular, coronary, or peripheral artery dis-
ease) complications. Such subdivision could only be possible once
they had reported signs or symptoms of any of those diseases or
had information in their medical records.
To participate in the study, all subjects read and signed an
informed consent form. The studywas previously approved by the
Research Ethics Committee of the University of São Paulo/Ribeirão
Preto campus. Investigators conducted the research in accordance
with the principles of the Declaration of Helsinki.
Estimated costs
The economic effects of outpatient diabetes care were assessed
from the SUS and society perspectives over the course of 1 year.
Direct and indirect costs were taken into account.
There were costs in Brazilian currency (R$) attributed to all
resources utilized for the year 2007, which were then converted
into US dollars during the analysis using a purchasing power par-
ity basis for 2005: US$1  R$ 1.4 [7].
Direct costs were estimated using a bottom-up approach for
primary data collection [8] and divided into medical and nonmed-
ical costs. The direct medical costs assessed included medica-
tions, diagnostic tests, procedures, medical supplies (such as
blood glucose test strips), visits with health professionals (physi-
cians, nurses, nutritionists, physical therapists, dentists, and psy-
chologists), and hospital costs for emergency room visits (includ-
ing provider fees only). Medications used were categorized into
four groups: diabetes and obesity, cardiovascular and dyslipide-
mia, psychiatric, and others (all other classes of medications).
The direct nonmedical costs assessed included expenses with
artificial sweeteners and diet products, patient transportation to
attend clinic visits and laboratory testing, and expenses for hiring
a temporary caregiver during a patient recovery period. Due to the
wide variety of urban means of transport available (bus, train,
subway, car), a minimum amount corresponding to two regular
bus fares (US$3.10) was set to assess transportation expenses.
Total direct outpatient costs of diabetes care were defined as
the sum of all direct medical and nonmedical costs. Primary data
collection on hospitalization costs was not performed.
Medical procedures, health professionals’ visits, and supplies
were assessed through reimbursements given to health centers
based on SUS management of Procedures, Medications, and Spe-
cial Supplies and Equipment System [9]. As for the assessment of
medications covered by SUS, the weighted mean of the last three wmedication purchases made by public health units in 2007 was
based on the BrazilianMinistry of Health price database [10]. Med-
ications purchased at discount pharmacies cost nearly asmuch as
those covered by SUS. Medications purchased at private pharma-
cies included the price of generic medications, if available; if not,
the corresponding brand-name drug was obtained online through
a publication on medication prices with an added tax of 18% [11].
The indirect costs assessed were absenteeism and resulting
loss of productivity for the patients and their caregivers, sick leave,
and early retirement. The human capital approachwas adopted to
estimate indirect costs. The mean monthly income and the value
of working hours were used to calculate workdays lost [8].
Statistical analysis
Data collected through questionnaires were electronically com-
piled by Epi-info 2000 (Centers for Disease Control and Prevention,
Atlanta, GA). The statistical analysis was performed using SAS/
STAT version 9 (SAS Institute, Inc, Cary, NC). Variance analysis
models were constructed to compare quantitative variables from
the different levels of care, diabetes complications, and different
disease durations. Fisher’s exact test was carried out for compar-
ison. A 5% significance level was set.
Results
Sample characteristics
There were a greater proportion of women receiving medical care
(66.5% women vs. 33.5% men). Mean age was 59.0  9.1 years and
mean duration of diabetes diagnosis was 11.2  7.8 years.
The self-reported prevalence of coronary artery disease was
70.4%, with a higher prevalence at the tertiary level compared to the
secondary and primary levels (P  0.001). The prevalence of self-
reported arterial hypertension (79.6%), cerebrovascular disease
(7.6%), and hypercholesterolemia (70.4%) were similar at all different
levels of care.
Home blood glucose monitoring was reported by 34.3% of the
sample (n  343).
Information on chronic diabetes complicationswas not available
in 38% of the sample (n  380) due to missing information in the
medical records.Outof the remainingpatients (n620), 28.9%hadat
least one microvascular complication (micro group; n  289), 17%
had at least onemacrovascular complication (macro group; n 171)
and16%hadat least onemicrovascular andonemacrovascular com-
plication associated (micro/macro group; n 160).
The mean monthly income in the sample was US$543.35 and
the income of each day of work was US$18.11.
Direct costs
Total direct outpatient cost of diabetes care was US$1335 per pa-
tient/year, out of which US$1014 per patient/year expended on
direct medical costs and US$332 per patient/year on non-medical
costs. (Table 1 in Supplemental Materials at: doi:10.1016/j.
jval.2011.05.009).
Total annual cost of medications for 1000 patients was
US$747,356; US$563,506 paid by the public health system (SUS)
(75.4%) and US$183,849 paid by patients in private pharmacies
(24.6%). The expenses per patient/year with different medication
groups were: US$249 with diabetes/obesity (n  959); US$397 with
ardiovascular/dyslipidemia (n 905); US$321 with psychiatric con-
itions (n 170), and US$285 with other medications (n 335). (See
able 2 in Supplemental Materials at: doi:10.1016/j.jval.2011.05.009).
The total cost of exams and procedures summed US$1216 per
atient/year and the cost for health professionals’ consultations
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(US$299 per patient/year; n  343).
Annual expenses with artificial sweeteners and diet products
amounted to US$258,617 (US$286 per patient). Expenses related to
blood pressuremonitoringwere reported by 62 patients (US$59 per
patient) and only 15 patients reported expenses with hiring a tem-
porary caregiver (US$599 per patient). Patient transportation costs
for attending consultations and/or undergoing diagnostic tests to-
taled US$50,964 (US$52 per patient).
There was an increment in direct costs with diabetes progres-
sion and presence of diabetes complications (data not shown).
Indirect costs
Total indirect costs were US$773,212 (US$773 per patient/year),
which corresponds to 36.7% of total diabetes costs. (See Table 1 in
Supplemental Materials found at: doi:10.1016/j.jval.2011.05.009).
The lost of workdays corresponded to a loss of productivity of
US$437 per patient/year from those who reported having an income
(n 829). A total of 32 (3.2%) and 74 (7.4%) subjects reported diabetes-
related sick leave and early retirement, respectively, associatedwith
US$103,680 and US$410,702 expenses paid by the government. Job
loss due to diabetes was reported by 127 subjects (12.7%).
There was an increment in indirect costs with diabetes pro-
gression and presence of diabetes complications (data not shown).
Total costs
In the sample studied, the sumof direct and indirect costs amounted
to US$2,108,287 for 1,000 patients per year (US$2,108 per patient).
Total costs of diabetes care was US$ 1144 per patient at the
primary care level, US$2445 at the secondary level and US$2810 at
the tertiary level, with significant differences among total costs at
the primary level and those at the secondary and tertiary levels
(P  0.01). (See Fig. 1A in Supplemental Materials found at: doi:
0.1016/j.jval.2011.05.009).
In regard to diabetes duration, there was an increment in total
osts as diabetes progressed: US$1971 per patient with diabetes
uration 10 years or fewer; US$2173 per patient in those with dia-
etes duration between 10 and 19 years andUS$2544 per patient in
hose with 20 years or more of diabetes duration (P  0.01 among
all the groups). (See Fig. 1B in Supplemental Materials found at:
doi:10.1016/j.jval.2011.05.009).
Total costs per patient from diabetes complications were as fol-
lows: US$2062 per patient in the micro group (n 289); US$2517 per
patient in the macro group (n 171) and US$3199 per patient in the
micro/macro group (n 160) (P 0.01 among all the groups). (See Fig.
1C in supplemental Materials found at: doi:10.1016/j.jval.2011.
05.009).
Discussion
ESCUDI is the first study conducted in Brazil showing a breakdown
of costs of type 2 diabetes outpatient care in the SUS. Data were
collected in eight cities with the purpose of describing health care
in different Brazilian regions (southern, southeastern, and north-
eastern). Total cost of diabetes outpatient care during a 1-year
period was US$2108 per patient/year, out of which 63.3% was di-
rect costs and 36.7% was indirect costs. As expected, costs in-
creased as diabetes progressed (23% cost increment in those with
10 or fewer years of diabetes duration compared to those with
diabetes duration of 20 years or more) and with the presence of
chronic complications (25% cost increment in those with both
complications compared to those with only one microvascular or
macrovascular complication). Similar results were described in a
previous cost analysis of chronic diabetes complications [12].There was no difference in direct costs between secondary and
tertiary levels of care, but in general, costs were higher than the pri-
mary care level, where majority of patients are being treated.
A great and significant portion of costs (36.7%) were due to
indirect costs of diabetes, which also include hidden expenditures
paid by society that are usually little known and not included in
government budget analyses. When comparing the annual costs
made by the individuals (nonmedical direct costs, purchasedmed-
ications, and loss of productivity) with their mean annual income
(US$6520), we could demonstrate that 14.4% of their income was
used for treatment.
The greatest portion of direct costs was attributed to medica-
tion (48.2%). Although the Brazilian health system has the respon-
sibility to provide drug treatment for any chronic disease, 24.6% of
the patients bought medicines from private pharmacies.
Previous studies on costs of diabetes clearly show that the
greatest proportion of costs is attributed to hospital admissions.
The CODE-2 study [13] demonstrated themedical costs of diabetes
care in eight European countries based on primary data collection
anddatabase analysis. The estimated cost per patient per yearwas
€2834 and the largest portion of these costs was attributed to hos-
pital admissions (55%), mostly due to chronic diabetes complica-
tions, whereas only a small portion accounted formedication (4%).
Those European results are hardly comparable to our Brazilian
ones because these two studies had different approaches and the
former included costs of hospital admissions, which are very high.
The most recent American study on diabetes costs [14] shows an
estimated cost of US$174 billion in 2007, out of which US$116 bil-
lion was spent on health resources and US$58 billion was attrib-
uted to loss of productivity. Similar to the CODE-2 study [13], the
largest portion of costs were attributed to hospital admissions
(50%), followed by medication and medical supplies (12%) [14].
Again, these results cannot be appropriately compared to the Bra-
zilian ones because different methods were used (top-down ap-
proach vs. bottom-up approach). The ratio of direct cost to indirect
cost was similar in the Brazilian andAmerican studies, reinforcing
the heavy burden of diabetes to individuals and society.
Rosa et al. [15] investigated the costs of public hospital admis-
sions in Brazil during 2 years (1999–2001) using diabetes as the
main diagnosis and the method of attributable risk associated to
all admissions. The estimated number of hospital admissions was
836,300 per year (49.3/104 inhabitants), with a cost of US$243,900
per year (14.4 million/104 inhabitants). Public expenditure related
to hospital admissions of individualswith diabeteswas expressive
(2.2% of the Brazilian Ministry of Health budget) [15].
Our studyhas some limitations, such as lack of knowledge on the
actual situation of patients with diabetes regarding their regional
distribution, access to care, and disease severity, as well as the fact
that cities were randomly selected for data collection and are not
representative of the whole country. Because the patient selection
processwasnot ideal, some selectionbias could be observed, suchas
that themajorityof includedpatientswerewomenorworkers.More-
over, considering the lackof informationonchronic complications in
medical records, we analyzed the results separately. By doing so, we
conclude that, regarding level of care, age, social level, or other iden-
tifiable factor that can be considered a systematic selection bias,
there were no differences between those individuals with available
datawhichallowed the classificationof thepresenceof chronic com-
plications (n 620) and those without (n 380).
For the above reasons, results obtained in this sample may not
accurately reflect average costs of diabetes care in thewhole country.
As a cost-of-illness study, the results were only descriptive, without
comparisons to other populations. The possibility to compare the
costs in a similar groupwithout diabeteswould in fact bemuchmore
informative tomanagersof theSUS.However, therearenopublished
cost studies with primary data collection of the general Brazilian
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ensure that the costs were attributed exclusively to diabetes.
The findings of our study indicate a serious economic threat
posed by diabetes that public authorities and all social sectors
have to face. The noninclusion of hospital costs in the analysis
resulted in an underestimate of the actual total cost of diabetes
care in Brazil. The high percentage of indirect costs reveals hidden
losses posed by diabetes that need to be taken into account. How-
ever, even with the inclusion of nonmedical and indirect costs in
the study, not all the harm caused by diabetes were considered.
There are intangible costs such as pain, suffering, and loss of qual-
ity of life that were not shown.
The increasing incidence and prevalence of diabetes evidenced
by epidemiologic studies worldwide represents a growing burden
thatmost health systems are unable to deal with. There is an imper-
ative need to develop and improve interventions toward prevention
of diabetes and its complications and to reorganize resources to im-
prove the effectiveness of health care. If this is not done, the public
financingofdiabetes treatmentwill beunviable inanear future,with
deleterious consequences for the health of the Brazilian population.
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